In the company’s news yesterday,
Novavax Inc. announced the vaccination of healthy volunteers in a phase II clinical trial of its VLP-based seasonal influenza vaccine. The randomized, placebo-controlled clinical trial will evaluate the safety and immunogenicity of different doses of its seasonal influenza VLP vaccine in about 300 healthy adults between 18 and 49 years of age. The volunteers will receive a single injection of either a placebo or vaccine to study the efficacy and safety of Novavax’s VLP vaccines.
According to Dr. Rahul Singhvi, president and CEO of Novavax, the company’s VLPs hold the potential as an effective prevention. The development of its VLP pandemic and seasonal flu vaccines in close proximity will allow the company to benefit from product synergies.
“We are delighted to initiate our seasonal influenza vaccine program in phase II human trials,” Dr. Singhvi stated. “VLPs are a very promising approach against influenza as we recently demonstrated with the announcement of favorable results in a phase IIa human clinical trial of our VLP based pandemic influenza vaccine. There are synergies to be gained in the development of our VLP pandemic and seasonal influenza vaccines that provide the Company unique advantages. For example, since both vaccines utilize the same manufacturing approach, safety information from either one of these influenza vaccine programs would compliment and support the other program which should reduce the overall development timeline for each program.”
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.
To sign up for “The QualityStocks Daily Newsletter” please visit http://www.qualitystocks.net/
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
